1. Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients
   Ashraf Z. Badros et al, 2005, JCO CrossRef
2. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
   Jérôme Moreaux et al, 2004 CrossRef
3. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti–multiple myeloma (MM) activity and overcome bortezomib resistance
   Dharminder Chauhan et al, 2004 CrossRef
4. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
   Dharminder Chauhan et al, 2007 CrossRef
5. Dexamethasone Inhibits Spheroid Formation of Thyroid Cancer Cells Exposed to Simulated Microgravity
   null Melnik et al, 2020, Cells CrossRef
6. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels
   Niels W. C. J. van de Donk et al, 2003 CrossRef
7. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance
   Dharminder Chauhan et al, 2003 CrossRef
8. Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
   Ying Chen et al, 2020, Front. Oncol. CrossRef
9. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
   Nur Najmi Mohamad Anuar et al, 2020, Front. Pharmacol. CrossRef
10. Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides
    Sanjeev Shangary et al, 2004 CrossRef
11. Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)
    Roy S. Herbst et al, 2004 CrossRef
12. Multiple myeloma with t(11;14): impact of novel agents on outcome
    Borja Puertas et al, 2023, Blood Cancer J. CrossRef